China Pharma Holdings Gross Profit

As of the most recent data (June 2026), CPHI shows a gross profit of $180B. That compares with $-660B in the prior-year period — up 127.1% year over year. That is above the Healthcare sector average of $65B. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CPHI's gross profit is now $180B (was $-660B) — a 127.1% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether China Pharma Holdings is outperforming or lagging.

The Healthcare sector average gross profit is about $65B. China Pharma Holdings is at $180B, which is higher that average. That is roughly 174.4% above the sector mean. Use the comparison chart on this page to see how CPHI stacks up against individual peers as well.

Tracking CPHI's gross profit over time shows whether China Pharma Holdings is scaling, shrinking, or reshaping that part of the business. The current reading is $180B That compares with $-660B in the prior-year period — up 127.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this gross profit page, Stockcircle has China Pharma Holdings's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect gross profit (currently $180B) with ownership activity and broader fundamentals.